Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2023

BUY
$2.66 - $5.61 $559,398 - $1.18 Million
210,300 New
210,300 $582,000
Q1 2022

May 09, 2022

SELL
$2.66 - $5.61 $559,398 - $1.18 Million
-210,300 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$5.18 - $8.48 $1.09 Million - $1.78 Million
210,300 New
210,300 $1.12 Million
Q3 2021

Nov 14, 2022

BUY
$8.46 - $12.42 $2.32 Million - $3.41 Million
274,300 New
274,300 $2.32 Million
Q3 2021

Nov 05, 2021

SELL
$8.46 - $12.42 $676,800 - $993,600
-80,000 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$12.19 - $28.17 $975,200 - $2.25 Million
80,000 New
80,000 $975,000
Q2 2021

Aug 10, 2021

SELL
$12.19 - $28.17 $975,200 - $2.25 Million
-80,000 Closed
0 $0
Q1 2021

May 09, 2022

BUY
$22.23 - $34.75 $1.78 Million - $2.78 Million
80,000 New
80,000 $1.94 Million
Q1 2021

May 07, 2021

SELL
$22.23 - $34.75 $2.22 Million - $3.48 Million
-100,000 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$29.47 - $35.0 $2.95 Million - $3.5 Million
100,000 New
100,000 $3.21 Million
Q4 2020

Feb 10, 2021

SELL
$29.47 - $35.0 $2.95 Million - $3.5 Million
-100,000 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$26.17 - $43.07 $2.62 Million - $4.31 Million
100,000 New
100,000 $3.02 Million
Q3 2020

Nov 10, 2020

SELL
$26.17 - $43.07 $2.62 Million - $4.31 Million
-100,000 Closed
0 $0
Q2 2020

Aug 13, 2021

BUY
$22.3 - $44.8 $2.23 Million - $4.48 Million
100,000 New
100,000 $4.22 Million
Q2 2020

Aug 07, 2020

SELL
$22.3 - $44.8 $2.23 Million - $4.48 Million
-100,000 Closed
0 $0
Q1 2020

May 07, 2021

BUY
$18.18 - $39.48 $1.82 Million - $3.95 Million
100,000 New
100,000 $2.5 Million

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $79.2M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.